key: cord-0493367-prc7t9xh authors: Zeng, Xiangxiang; Song, Xiang; Ma, Tengfei; Pan, Xiaoqin; Zhou, Yadi; Hou, Yuan; Zhang, Zheng; Karypis, George; Cheng, Feixiong title: Repurpose Open Data to Discover Therapeutics for COVID-19 using Deep Learning date: 2020-05-21 journal: nan DOI: nan sha: 735308049ea1c51c22af3228b8a7449844faf98a doc_id: 493367 cord_uid: prc7t9xh There have been more than 850,000 confirmed cases and over 48,000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic, caused by novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), in the United States alone. However, there are currently no proven effective medications against COVID-19. Drug repurposing offers a promising way for the development of prevention and treatment strategies for COVID-19. This study reports an integrative, network-based deep learning methodology to identify repurposable drugs for COVID-19 (termed CoV-KGE). Specifically, we built a comprehensive knowledge graph that includes 15 million edges across 39 types of relationships connecting drugs, diseases, genes, pathways, and expressions, from a large scientific corpus of 24 million PubMed publications. Using Amazon AWS computing resources, we identified 41 repurposable drugs (including indomethacin, toremifene and niclosamide) whose therapeutic association with COVID-19 were validated by transcriptomic and proteomic data in SARS-CoV-2 infected human cells and data from ongoing clinical trials. While this study, by no means recommends specific drugs, it demonstrates a powerful deep learning methodology to prioritize existing drugs for further investigation, which holds the potential of accelerating therapeutic development for COVID-19. As of April 22, 2020 , there have been more than 850,000 confirmed cases and over 48,000 deaths from Coronavirus Disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2, in the United States alone. 1 However, there are currently no proven effective antiviral medications against COVID-19. 2 There is an urgent need for the development of effective treatment strategies for COVID-19. Traditional de novo drug discovery was estimated that pharmaceutical companies spent $2.6 billion in 2015 for the development of an FDA-approved new chemical entity drug. 3 Drug repurposing, a drug discovery strategy from existing drugs, offers an promising way for the development of prevention and treatment strategies for COVID-19. 4 In a randomized, controlled, open-label trial 5 Prior knowledge of networks from large scientific corpus of publications offers a deep biological perspective for capturing the relationships between drugs, genes and diseases (including COVID-19). Yet, extracting connections from a large-scale repository of structured medical information is challenging. In this study, we present the state-of-the-art knowledge graph-based, deep learning methodologies for rapid discovery of drug candidates to treat COVID-19 from 24 million PubMed publications. Via systematic validation using transcriptomics and proteomics data generated from SARS-CoV-2 infected human cells and the ongoing clinical trial data, we successfully identified 41 drug candidates that can be further tested in large-scale randomized control trials for potential treatment of COVID-19. Pipeline of CoV-KGE 5 Here we present a knowledge graph-based, deep learning methodology for drug repurposing in COVID-19, termed CoV-KGE (Figure 1 ). Our method uses DGL-KE, developed by our Amazon's AWS AI Laboratory 13 , to efficiently learn embeddings of large knowledge graphs. Specifically, we construct a knowledge graph from 24 million PubMed publications 14 and DrugBank 15 , including 15 million edges across 39 types of relationships connecting drugs, diseases, genes, anatomies, pharmacologic classes, gene/protein expression, and others (cf. Supplementary Tables 1 and 2 ). In this knowledge graph, we represent the Coronaviruses (CoVs) by assembling multiple types of known CoVs, including SARS-CoV-1, MERS-CoV, HCoV-229E, and HCoV-NL63 as described in our recent study 9 . We next utilize DGL-KE's knowledge graph embedding model, RotatE 16 , to learn representations of the entities (e.g., drugs and targets) and relationships (e.g., inhibition relation between drugs and targets) in an informative, low-dimensional vector space. In this space, each relationship type (e.g., antagonists or agonists) is defined as a rotation from the source entity (e.g., hydroxychloroquine) to the target entity (e.g., toll-like receptor 7/9 (TLR7/9)) (cf. Methods). After mapping drugs, CoVs, and the treatment relationships to a complex vector space using RotatE, the top-100 most relevant drugs are selected as 6 candidate for CoVs in the treatment relation space (Supplementary Figure 1 ). Using the ongoing COVID-19 trial data (https://covid19-trials.com/) as a validation set, CoV-KGE has the larger area under the receive operating characteristic curve (AUROC = 0.85, Figure 2 ) in identifying repurposable drugs for COVID-19. We next employ t-SNE (t-distributed stochastic neighbor embedding algorithm 17 ) to further investigate the low-dimensional node representation learned by CoV-KGE. Specifically, we project drugs grouped by the first-level of the Anatomical Therapeutic Chemical (ATC) classification systems code onto two-dimensional space. Figure 3A indicates that CoV-KGE is able to distinguish 14 types of drugs grouped by ATC codes, consistent with a high Table 3 ). We next turn to highlight three types of predicted drugs for COVID-19, including antiinflammatory agents, selective estrogen receptor modulators (SERMs), and antiparasitics ( Figure 3A ). Given the well-described lung pathophysiological characteristics and immune responses (cytokine storms) of severe COVID-19 patients, drugs that dampen the immune responses may offer effective treatment approaches for COVID-19. 18, 19 As shown in Figure 3A , we computationally identified multiple antiinflammatory agents for COVID-19, including indomethacin and melatonin. Indomethacin, an approved cyclooxygenases (COXs) inhibitor, has been widely used for its potent anti-inflammatory and analgesic properties 20 . Indomethacin has been reported to have antiviral properties, including SARS-CoV-1 20 , and SARS-CoV-2 21 . Importantly, preliminary in vivo observation showed that oral indomethacin (1 mg/kg body weight daily) reduced the recovery time of SARS-CoV-2 infected dogs. 21 Melatonin plays a key role in the regulation of human circadian rhythm that alters the translation of thousands of genes, including melatonin-mediated anti-inflammatory and 8 immune-related effects for COVID-19. Melatonin has various antiviral activities by suppressing multiple inflammatory pathways 22, 23 (including IL6, IL-1β, and TNFα, etc.) --these inflammatory effects are directly relevant given the welldescribed lung pathophysiological characteristics of severe COVID-19 patients. The melatonin's mechanism-of-action may also help explain the epidemiologic observation that children, who have naturally high melatonin levels, are relatively resistant to COVID-19 disease manifestations, while older individuals, who have decreasing melatonin levels with age, are a very high-risk population. 24 In addition, exogenous melatonin administration may be of particular benefit to older patients given an aging-related reduction of endogenous melatonin levels and vulnerability of older individuals to the lethality of SARS-CoV-2. 24 An overexpression of estrogen receptor has played a crucial role in inhibiting viral replication and infection. 25 Several selective estrogen receptor modulators (SERMs), including clomifene, bazedoxifene, and toremifene, are identified as promising candidate drugs for COVID-19 ( Figure 3B) . Toremifene, the first generation of nonsteroidal SERM, was reported to block various viral infections at low micromolar concentration, including Ebola virus 26, 27 , MRES-CoV 28 , SARS-CoV-1 29 , and SARS-CoV-2 30 (Figure 3A) . Toremifene prevents fusion between the viral and endosomal membrane by interacting with and destabilizing the virus glycoprotein, and eventually blocking replications of the Ebola virus. 26 The underlying antiviral mechanisms 9 of SARS-CoV-1 and SARS-CoV-2 for toremifene remains unclear and are currently being investigated. Toremifene has been approved for the treatment of advanced breast cancer 31 and has also been studied in men with prostate cancer (~1,500 subjects) with reasonable tolerability. 32 Toremifene is 99% bound to plasma protein with good bioavailability and typically administered at a dosage of 60 mg orally. 33 In summary, toremifene offers a promising candidate drug with ideal pharmacokinetics properties to be tested in COVID-19 clinical trials directly. Hydroxychloroquine and chloroquine phosphate, two approved antimalarial drugs, though lacking strong clinical evidence, were authorized by the U.S. FDA for treatment of COVID-19 patients using emergency use authorizations. 2 In this study, we identified that both hydroxychloroquine and chloroquine are among the predicted candidates for COVID-19 ( Figure 3A) . Between the two, hydroxychloroquine's in vitro antiviral activity against SARS-CoV-2 is stronger than that of chloroquine (hydroxychloroquine: 50% effective concentration (EC50) = 6.14 μM where chloroquine: EC50 = 23.90 μM) 34 . Hydroxychloroquine and chloroquine are known to increase the pH of endosomes, which inhibits membrane fusion, a required mechanism for viral entry (including SARS-CoV-2) into the cell 19 . Additionally, the potential benefit replicates poorly in multiple animals, including dogs, pigs, chickens, and ducks, which limits preclinical animal studies 39 . In this study, we present CoV-KGE, a powerful, integrated AI methodology that can be used to quickly identify drugs that can be repurposed for the potential treatment of COVID-19. Our approach can minimize the translational gap between preclinical testing results and clinical outcomes, which is a significant problem in the rapid development of efficient treatment strategies for the COVID-19 pandemic. From a translational perspective, if broadly applied, the network tools developed here could help develop effective treatment strategies for other emerging infectious diseases and other emerging complex diseases as well. In this study, we constructed a comprehensive knowledge graph (KG) from GNBR 14 and DrugBank 41 . First, from GNBR, we included in the KG relations corresponding to drug-gene interactions, gene-gene interactions, drugdisease associations, and gene-disease associations. Second, from 12 DrugBank, we selected the drugs whose molecular mass is greater than 230 daltons and also exist in GNBR-resulting in 3,481 FDA-approved and clinically investigational drugs. For these drugs, we included in the KG relationships corresponding to the drug-drug interactions, and the drug-sideeffects, drug ATC codes, drug-mechanism-of-action, drug-pharmacodynamics, and drug-toxicity associations. Third, we included the experimentally discovered coronaviruses-gene relationships from our recent work in the KG. 9 Fourth, we treated the COVID-19 context by assembling six types of Table 2 ). Models for computing knowledge graph embeddings learn vectors for each of the entities and each of the relation types so that they satisfy certain properties. In our work we learned these vectors using the RotatE model. 42 Given an edge in the knowledge graph represented by the triplet (head-entity, relation-type, and tail-entity), RotatE defines each relation type as a rotation from the head entity to tail entity in the complex vector space. Specifically, if 13 ℎ, # are the vectors corresponding to the head and tail entities, respectively and $ is the vector corresponding to the relation type, RotaE tries to minimize the distance where ∘ denotes the Hadamard (element-wise) product. In order to minimize the distance between the head and the tail entities where σ is sigmoid function, γ is a margin hyperparameter with γ > 0, (ℎ ; , $, # ; ) is a negative triplet, and :(ℎ ; , $, # ; ) is the probability of occurrence of the corresponding negative sample. We divide the triplets (e.g., a relationship among drug, treatment, and disease) into training set, validation set, and test set in a 7:1:2 manner. We selected the embedding dimensionality of dim=200 for nodes and relations. The RotatE is trained for 16000 epochs with batch size 1024 and 0.1 as the learning rate. We choose γ = 12 as the margin of the optimization function in Supplementary Note 2. We performed the gene set enrichment analysis to further validate the predicted drug candidates from CoV-KGE. We first collected three differential 16 We introduced the area under the receiver operating characteristic (ROC) curve (AUROC) several evaluation metrics for evaluating performance of drug-target interaction prediction. The area under the receiver operating characteristic (ROC) curve (AUROC) 49 is the global prediction performance. The ROC curve is obtained by calculating the true positive rate (TPR) and the false positive rate (FPR) via varying cutoff. Supplemental Information can be found online. Source code and data can be downloaded from https://github.com/ChengF-Lab/CoV-KGE. patients 40 , combination therapy with antiviral agents (toremifene or niclosamide) and with anti-inflammatoray agents (melatonin or indomethacin) may offer promising treatment approach for COVID-19, which is warranted to be tested in the randomized controlled trials further. An interactive web-based dashboard to 17 track COVID-19 in real time Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A Review The $2.6 billion pill--methodologic and policy considerations Coronavirus puts drug repurposing on the fast track A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing Systems biology-based investigation of cellular antiviral drug targets identified by gene-trap insertional mutagenesis Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 Network-based approach to prediction and populationbased validation of in silico drug repurposing Network-based prediction of drug combinations A genome-wide positioning systems network algorithm for in silico drug repurposing Deep Graph Library: Towards Efficient and Scalable Deep Learning on Graphs A global network of biomedical relationships derived from text DrugBank 5.0: a major update to the DrugBank database for 2018 ROTATE: Knowledge graph embedding by relational rotation in complex space. ICLR Visualizing data using t-SNE Clinical and immunologic features in severe and moderate Coronavirus Disease SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion Indomethacin has a potent antiviral activity against SARS coronavirus Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo Ebola virus disease: potential use of melatonin as a treatment Beneficial actions of melatonin in the management of viral infections: a new use for this "molecular handyman Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China A Structure-informed atlas of human-virus interactions Toremifene interacts with and destabilizes the Ebola virus glycoprotein FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study Prostate cancer and prostatic intraepithelial neoplasia: true, true, and unrelated? Effect of toremifene on clinical chemistry, hematology and hormone levels at different doses in healthy postmenopausal volunteers: phase I study Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin Fatal toxicity of chloroquine or hydroxychloroquine with metformin in mice SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2 Clinical and immunologic features in severe and moderate Coronavirus Disease DrugBank 5.0: a major update to the DrugBank database Knowledge graph 22 embedding by relational rotation in complex space DGL-KE: Training Knowledge Graph Embeddings at Scale Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus SREBP-dependent lipidomic reprogramming as a broadspectrum antiviral target The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Discovery and preclinical validation of drug indications using compendia of public gene expression data Evaluation: from precision, recall and F-measure to ROC, informedness, markedness and correlation We acknowledge support from the Amazon Cloud, for credits to AWS ML Services. The content of this publication does not necessarily reflect the views of the Cleveland Clinic. The authors declare no competing interests.